About US
Contact us
-
GSK-Bharat vaccine deal; Dr. Reddy’s roller coaster; Sandoz sells U.S. genericsBy scooping up GlaxoSmithKline's Chiron Behring Vaccines subsidiary, Bharat Biotech hastaken another step toward its goal ofbecomingthe world's largest vaccine maker in terms of product numbers. Dr.2019/2/25
-
Pipeline-hungry Bayer antes up on Vitrakvi, just as Roche’s would-be rival gets faster FDA reviewEager to pump up its pipeline—and hungry for present-day sales—Bayer has taken its chance to carve a piece out of Eli Lilly's $8 billion Loxo Oncology buyout. German drugmaker decided totakefull cont2019/2/20
-
Egalet's 70% price increase shows the buy-and-hike strategy is alive and wellThink the entire pharma industry has moved past the old strategy of buying drug rights, jacking up prices and reaping the rewards? Think again. Big Pharma may be limiting hikes to the single dig2019/2/20
-
NICE recommends Roche’s breast cancer drug pertuzumabThe UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Roche’s Perjeta (pertuzumab) by the National Health Service (NHS) to treat early HER2-positive breast canc2019/2/19
-
Merck Group and Pfizer announce positive results for combo therapy for RCCPfizer and German-based Merck Group have published promising interim results from their Phase III JAVELIN Renal 101 trial evaluating the efficacy and safety of Bavencio (avelumab) and Inlyta (axitini2019/2/19
-
Swayed by discounts, NICE finally backs Roche's Perjeta for postsurgery breast cancerLooks like the third time was a charm for Roche’s Perjeta when it comes to postsurgery treatment of HER2-positive breast cancer in England. After two previous rejections, the cost watchdogs at the Na2019/2/18
-
AstraZeneca rides high on sales rebound after cancer drugs, China once again pull throughIt's confirmed: AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to cancer drugs Tagrisso and Lynparza—and once again, China. The British drugmake2019/2/18
-
Staggering under load of talc litigation, J&J supplier Imerys America seeks shelter in bankruptcyFacing “historic” liabilities from thousands of lawsuits claiming its products caused cancer, Johnson & Johnson talc supplier Imerys Talc America and two associated companies filed for bankruptcy2019/2/15
-
Teva forecasts worse-than-expected ‘trough year’ as generics hammer MS drug CopaxoneShares of Teva fell nearly 12% in pre-market trading to $16.80 after the company’s executives conceded during the fourth-quarter earnings report that 2019 would be an even tougher year than analysts h2019/2/15
-
FDA panel supports Janssen’s esketamine nasal spray for depressionJanssen Pharmaceutical has secured recommendation from the US Food and Drug Administration (FDA) advisory committees for the approval of its esketamine nasal spray Spravato to treat adults with treatm2019/2/14